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electrophoresis,[11] and potentiometric[12] determination 
techniques. The official method for the determination 
of FLX is non-aqueous titration using perchloric acid 
as a titrant, in pure form, and  spectrophotometry   
in  tablets.[4] Gilliland et al.[13] reported the LC-MS / 
MS determination of Flavoxate and its metabolite 
3-Methylflavone-8-Carboxylic acid (MFA) in Human 
NaF Plasma. 
The retention time of the reported HPLC methods is more 
than five minutes and the flow rate of the mobile phase is 
1.5 ml/min, which requires a greater mobile phase for the 
determination of flavoxate. Hence, in the present study 
it was intend to develop a rapid, economical, simple, and 
precise RP HPLC method for the estimation of flavoxate 
HCl in bulk and formulations. 
INTRODUCTION
Flavoxate hydrochloride (FLX, 3-methylflavone-8-carboxylic 
acid β-piperidinoethyl ester hydrochloride, C24H26ClNO4, 
MW : 427.93, Figure 1), belongs to a series of flavone 
derivatives, which exhibit strong smooth muscle relaxant 
activity, with selective action on the pelvic.[1] It is used for 
the symptomatic relief of pain, urinary frequency, and 
incontinence associated with inflammatory disorders of 
the urinary tract. It is also used for relief of vesicourethral 
spasms resulting from instrumentation or surgery.[2] 
The literature survey reveals that FLX was estimated 
from its pharmaceutical preparations by using Ultraviolet 
spectrophotometry,[3,4]  high  performance  liquid 
chromatography (HPLC),[5-9] Voltammetry,[10] capillary 
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The objective of the study was to develop a high performance liquid chromatography (HPLC) method using ultra 
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is  reliable, reproducible, and suitable for routine quantitative use.
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EXPERIMENTAL
Chromatographic conditions
The HPLC Agilent 1200 system (Germany) was equipped 
with an auto injector (100 μl syringe) and connected to 
a variable diode array wavelength detector and recorder. 
A Zorbax eclipse XBD-C18 reversed phased column 
(150 mm x 4.6 mm. i.d.) bonded on to 5 µm silica gel, 
manufactured by Agilent, was used for analysis. A mixture 
of acetonitrile : 0.1% formic acid in water (75 : 25 v/v, pH 
3.0) was used as the mobile phase. The flow rate was 0.8 ml/
min, wavelength was 218 nm, and the injection volume was 
20 μl. The analysis was carried out at ambient temperature. 
Reagents
All the chemicals were of analytical grade and used without 
further purification. The water was distilled and deionized 
by passing it through the water purification system. HPLC 
grade Acetonitrile (Chromasolv) and AR grade formic 
acid from Sigma Aldrich (Switzerland) were used in this 
study. The standard drug samples of the flavoxate HCl 
and ibuprofen used were supplied by Mankind Pharma 
Ltd., India.
Standard and sample preparation
Standard stock solution at a concentration of 1 mg/ml 
FLX was prepared by dissolving an appropriate amount of 
the standard drug in the mobile phase. Internal standard 
ibuprofen (IBU) solution was prepared by dissolving 10 
mg of IBU in 10 ml of the mobile phase.  Twenty tablets 
of FLX as HCl salt each containing 200 mg were weighed 
and powdered. A quantity equivalent to 10 mg of FLX, as 
HCl salt powder, was weighed and transferred to a 10 ml 
volumetric flask containing 8 ml of the mobile phase and 
sonicated for 10 minutes. Subsequently, the volume was 
made up to the mark with the mobile phase. The solution 
was filtered using a nylon 0.45 µm membrane filter. This 
solution was diluted with the mobile phase to get the 
concentration in the Beers range.
Method validation
The method validation parameters, such as, specificity, 
linearity, accuracy, precision, limit of detection, limit 
of quantification, and robustness were verified as per 
the International Conference on Harmonization (ICH) 
guidelines.[14]
Specificity
The specificity of the method was confirmed by 
comparison of chromatograms obtained from the standard 
and the samples. 
Linearity and range
Appropriate aliquots of standard stock solution were taken 
in 10 ml volumetric flasks. Internal standard IBU solution 
(0.5 ml) was added to all the volumetric flasks and the 
volume was brought up to the mark with the mobile phase 
to get the following concentrations: 1, 10, 50, 100, 150, 
200, and 250 μg/ml of FLX and 50 μg/ml of IBU. Twenty 
microliters of the standard and sample were injected and 
the chromatograms were recorded. 
Accuracy (% Recovery)
The accuracy study was carried out by the standard addition 
method. Known amounts of standard solution of FLX 
(50, 100, and 150 μg/ml) were added to a sample solution 
of FLX (50 μg/ml), with IBU as the internal standard (50 
μg/ml). Each solution was injected in triplicate and the 
Figure 1: Structure of Flavoxate HCl Figure 2: Representative chromatograms of Flavoxate HCl (50 µg/
ml) (Rt 1.44) and internal standard Ibuprofen (50 µg.mL-1) (Rt 3.50) 
measured at 218 nm
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percentage recovery was calculated by calculating the ratios 
of the peak areas.
Precision
Standard solutions having concentrations of 1, 10, 50, 100, 
150, 200, and 250 μg/ml of FLX and 50 μg/ml of IBU 
were prepared. For the intra-day studies, three repeated 
measurments of these solutions were carried out within a 
day and %RSD was calculated. In the inter-day variation 
studies, three repeated measurements of the same solutions 
were carried out on three consecutive days and %RSD was 
calculated. 
Limit of detection and limit of quantification
The limit of detection (LOD) and limit of quantification 
(LOQ) were calculated from the standard deviation of 
responses and slopes using signal-to-noise ratio as per 
ICH guidelines.[14] 
Robustness
Robustness of the method was studied by changing the 
extraction time of FLX, from dosage form by five minutes, 
composition of mobile phase by 2% of organic phase, flow 
rate by 0.1 ml/min, and wavelength by 1 nm. 
System suitability test
System suitability tests were used to verify the resolution 
and repeatability of the system. The parameters used in 
this test were asymmetry of the chromatographic peak, 
peak resolution, and repeatability, as relative standard deviation 
(RSD) of the peak area, for repeated injections. The 
precision of the instrument was checked by repeatedly 
injecting a solution of FLX (100 μg/ml). 
RESULTS AND DISCUSSION
Chromatographic conditions were developed empirically 
by selecting various solvents such as water, acetonitrile, and 
methanol in different concentrations, and the retention time 
and resolution were assessed to get optimum conditions. 
Under the established chromatographic condition, flavoxate 
HCl and internal standard (IS) peaks were well-resolved. 
As the system suitability parameters such as tailing factor 
and theoretical plate numbers were within the acceptable 
limits, the resolution of peaks were considered optimum. 
Retention time for FLX was 1.44 minutes, whereas, for IBU 
it was 3.50 minutes [Figure 2], indicating the rapid analysis 
of FLX. The calibration curves were constructed by plotting 
ratios of the peak areas of FLX and peak areas of IBU 
versus concentration of FLX, and the regression equations 
were calculated. Each response was the average of three 
determinations. The results [Table 1] obtained showed that 
the linearity range was 1 – 250 μg/ml. The corresponding 
regression equation was found to be: Y = 0.022 (X) + 
0.0052 (Y is peak area ratio of FLX to IS and X is FLX 
concentration) with a correlation coefficient of 0.9995. 
The recovery study showed that the mean recovery was 
99.6% and the RSD for three samples was lower than 2.0%. 
The RSD values of intra-day and inter-day were found to 
be in the range of 0.05 – 0.43 and 0.15 – 0.65, respectivly.   
As these parameters were within the acceptable range, it was 
inferred that the method was precise. The accuracy of the 
developed method was assessed by the standard addition 
method and the RSD was found to be within the acceptable 
limit [Table 2]. The limit of quantification (LOQ) of the 
method, defined as the minimum concentartion that could 
be measured, was found to be 0. 69 μg/ml. The limit of 
detection (LOD) was 0.23 µg/ml [Table 1]. The method 
was found to be robust as the results were not significantly 
affected by the slight variation in the extraction time, 
composition of mobile phase, flow rate, and wavelength. 
The chromatographic parameters such as selectivity and 
peak symmetry were within the range, and %RSD of 
repeatability was found to be 0.84, which was found to 
be satisfactory. The number of theoretical plates and the 
tailing factor were observed to be satisfactory [Table 1].
Analysis of marketed formulation
The proposed validated RP-HPLC method was successfully 
Table 1: Summary of regression analysis and validation 
parameters 
Parameters Values*
Regression analysis
Slope 0.022
Intercept 0.0052
Correlation coefficient 0.9995
Validation parameters
LOD (μg/ml) 0.23
LOQ (μg/ml) 0.69
Accuracy (%) ± % RSD 99.6 ± 1.51
Precision (% RSD)
Intra-day (n = 3) 0.05 – 0.43
Inter-day (n = 3) 0.15 – 0.65
Repeatability (% RSD) 0.84
System suitability test parameters 
Retention time (min) ± % RSD 1.44 ±0.05
Tailing factor ± % RSD 1.03 ± 0.1
Theoretical plates ± % RSD 11169 ± 1.95J Young Pharm Vol 2 / No 3  283
applied to determine FLX in two marketed formulations. 
The mean percentages of FLX were found to be 99.6 
± 1.51 and 101.1±1.02, which were comparable to the 
corresponding labeled amounts [Table 3]. Furthermore, 
the matrix components, for example, the excipients, did 
not interfere with the analyte.
CONCLUSION
The validated RP-HPLC method employed here has proved 
to be rapid, simple, specific, accurate, precise, sensitive, and 
robust. It can be successfully used for the routine analysis 
of FLX in bulk and in solid dosage form.
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Table 2: Recovery study data of FLX
Std. FLX conc. 
mcg/ml
Sample FLX conc. mcg/ml Total amount of FLX from 
Std. graph mcg/ml*
Recovery of standard 
drug mcg/ml
% Recovery of standard
50
100
150
50
50
50
98.7
151.3
197.6
48.7
101.3
147.6
97.4
101.3
98.4
*Mean value of the three determinations
Table 3: Assay result for Flavoxate HCl (200 mg per tablet) in the formulation product
Formulation No. FLX in label claim  
(mg)
Total amount of FLX 
found* (mg)
% of FLX found  % RSD
1 200 199.2 99.6 1.5
2 200 201.6 101.1 1.0
*Mean value of the three determinations 
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